- Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
-
Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB
- KMID: 2521583
- Cancer Res Treat.
- 2021 Oct;53(4):1084-1095.
- doi: 10.4143/crt.2020.1381
Purpose We evaluated study outcomes in patients enrolled in Asian regions in the phase III EMBRACA trial of talazoparib vs. chemotherapy. Materials and Methods Patients with human epidermal growth factor... -
- CITED
-
- Close
- SHARE
-
- Close
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
-
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki , Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T
- KMID: 2417858
- Cancer Res Treat.
- 2018 Jul;50(3):691-700.
- doi: 10.4143/crt.2017.280
PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
